Living

US FDA extends review of AstraZeneca's experimental breast cancer pill

By Reuters Reuters
The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS/Rachel Wisniewski
The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS/Rachel Wisniewski Rachel Wisniewski Reuters

AstraZeneca said on Wednesday the U.S. Food and Drug Administration has extended its review deadline for its experimental breast cancer pill camizestrant to assess additional data.

(Reporting by Ankita Bora in Bengaluru)

Copyright Reuters or USA Today Network via Reuters Connect

This story was originally published May 26, 2026 at 11:23 PM.

Get one year of unlimited digital access for $159.99
#ReadLocal

Only 44¢ per day

SUBSCRIBE NOW